News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard September 6, 2023 Immunic to Participate in Industry and Investor Conferences in September August 17, 2023 Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis August 3, 2023 Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 1, 2023 Immunic to Participate in Investor and Scientific Conferences in August July 27, 2023 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update June 29, 2023 Immunic to Participate in Scientific and Investor Conferences in July May 30, 2023 Immunic to Participate in Scientific and Investor Conferences in June May 17, 2023 Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis May 11, 2023 Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update May 9, 2023 Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update Show 5102550100 per page«123456789…16»
